280 related articles for article (PubMed ID: 33963708)
1. [Synergistic effect of polysaccharide from
Li P; Yuan P; Que Y; Liu X; Wang G
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Apr; 41(4):504-513. PubMed ID: 33963708
[TBL] [Abstract][Full Text] [Related]
2.
Ma L; Ai F; Xiao H; Wang F; Shi L; Bai X; Zhu Y; Ma W
Front Pharmacol; 2024; 15():1367747. PubMed ID: 38576495
[No Abstract] [Full Text] [Related]
3. Resveratrol elicits anti-colorectal cancer effect by activating miR-34c-KITLG in vitro and in vivo.
Yang S; Li W; Sun H; Wu B; Ji F; Sun T; Chang H; Shen P; Wang Y; Zhou D
BMC Cancer; 2015 Dec; 15():969. PubMed ID: 26674205
[TBL] [Abstract][Full Text] [Related]
4. IFI6 Downregulation Reverses Oxaliplatin Resistance of Colorectal Cancer Cells by Activating the ROS-Induced p38MAPK Signaling Pathway.
Huang C; Zhou T; Ma L; Zhao S
Biol Pharm Bull; 2023; 46(1):26-34. PubMed ID: 36596524
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin F
Wang YJ; Xie XL; Liu HQ; Tian H; Jiang XY; Zhang JN; Chen SX; Liu T; Wang SL; Zhou X; Jin XX; Liu SM; Jiang HQ
World J Gastroenterol; 2023 Oct; 29(39):5452-5470. PubMed ID: 37900995
[TBL] [Abstract][Full Text] [Related]
6. Dihydrotanshinone I Inhibits the Proliferation and Growth of Oxaliplatin-Resistant Human HCT116 Colorectal Cancer Cells.
Wang M; Xiang Y; Wang R; Zhang L; Zhang H; Chen H; Luan X; Chen L
Molecules; 2022 Nov; 27(22):. PubMed ID: 36431875
[TBL] [Abstract][Full Text] [Related]
7. Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species-mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin-resistant colorectal cancer cells.
Zhang Z; Shen C; Zhou F; Zhang Y
Drug Dev Res; 2023 May; 84(3):542-555. PubMed ID: 36779379
[TBL] [Abstract][Full Text] [Related]
8. P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions.
Zhang J; Li C; Sun L; Sun D; Zhao T
Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37921068
[TBL] [Abstract][Full Text] [Related]
9. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
[TBL] [Abstract][Full Text] [Related]
10. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
[TBL] [Abstract][Full Text] [Related]
11. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice.
Li X; Xia L; Ouyang X; Suyila Q; Su L; Su X
Protein Pept Lett; 2019; 26(7):512-522. PubMed ID: 30950338
[TBL] [Abstract][Full Text] [Related]
12. Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs.
Martin-Fernandez C; Bales J; Hodgkinson C; Welman A; Welham MJ; Dive C; Morrow CJ
Mol Cancer Res; 2009 Jun; 7(6):955-65. PubMed ID: 19509113
[TBL] [Abstract][Full Text] [Related]
13. Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-κB-Nrf2 signaling in colorectal cancer cell.
Wang Z; Sun X; Feng Y; Wang Y; Zhang L; Wang Y; Fang Z; Azami NLB; Sun M; Li Q
Phytomedicine; 2021 Feb; 82():153414. PubMed ID: 33461143
[TBL] [Abstract][Full Text] [Related]
14. [ASPP2 inhibits oxaliplatin-induced autophagy and promotes apoptosis of colon cancer cells].
Wang B; Qiao L; Shi Y; Feng X; Chen D; Guo H
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jul; 31(7):898-904. PubMed ID: 26146058
[TBL] [Abstract][Full Text] [Related]
15. Oxymatrine synergistically enhances antitumor activity of oxaliplatin in colon carcinoma through PI3K/AKT/mTOR pathway.
Liu Y; Bi T; Wang Z; Wu G; Qian L; Gao Q; Shen G
Apoptosis; 2016 Dec; 21(12):1398-1407. PubMed ID: 27671687
[TBL] [Abstract][Full Text] [Related]
16. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145.
Gao R; Fang C; Xu J; Tan H; Li P; Ma L
Arch Biochem Biophys; 2019 Mar; 663():183-191. PubMed ID: 30639170
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin-loaded nanoemulsion containing
Al-Otaibi WA; AlMotwaa SM
Drug Deliv; 2022 Dec; 29(1):2190-2205. PubMed ID: 35815706
[TBL] [Abstract][Full Text] [Related]
18. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
Alzoubi S; Brody L; Rahman S; Mahul-Mellier AL; Mercado N; Ito K; El-Bahrawy M; Silver A; Boobis A; Bell JD; Hajji N
Oncotarget; 2016 Jul; 7(28):44505-44521. PubMed ID: 27283986
[TBL] [Abstract][Full Text] [Related]
19. Low-dose orlistat promotes the therapeutic effect of oxaliplatin in colorectal cancer.
Zhang Q; Zhou Y; Feng X; Gao Y; Huang C; Yao X
Biomed Pharmacother; 2022 Sep; 153():113426. PubMed ID: 36017794
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer.
Wang K; Liu L; Zhang T; Zhu YL; Qiu F; Wu XG; Wang XL; Hu FQ; Huang J
Int J Nanomedicine; 2011; 6():3207-18. PubMed ID: 22238509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
